Cellular engineering of HSV-tk transduced, expanded T lymphocytes for graft-versus-host disease management

Acta Haematologica

Volumn 110, Issue 2-3, 2003, Pages 121-131

  Burger, Scott R ^a,b   Kadidlo, Diane M ^c   Basso, Lisa ^b   Bostrom, Nancy ^c   Orchard, Paul J ^b  

^a Advanced Cell and Gene Therapy   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

Author keywords

Allogeneic T lymphocytes; Cell therapy; Graft versus host disease; HSV tk; Suicide genes

Indexed keywords

GANCICLOVIR; NERVE GROWTH FACTOR RECEPTOR; PRODRUG; THYMIDINE KINASE; VIRUS ENZYME;

ADOPTIVE IMMUNOTHERAPY; BIOENGINEERING; BIOSAFETY; CELL SELECTION; DRUG BLOOD LEVEL; DRUG EFFECT; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SCALE UP; SIGNAL TRANSDUCTION; SUICIDE GENE; SURGICAL TECHNIQUE; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME; VIRUS INFECTION;

ADOPTIVE TRANSFER; GENES, TRANSGENIC, SUICIDE; GRAFT VS HOST DISEASE; HUMANS; SIMPLEXVIRUS; T-LYMPHOCYTES; THYMIDINE KINASE;

EID: 0242365546     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072461     Document Type: Review

References (37)

1. Davies SM, Wagner JE, Weisdorf DJ, Shu XO, Blazar BR, Nright H, Mcglave PB, Ramsay NK: Unrelated donor bone marrow transplantation for hematological malignancies - Current status. Leukemia Lymphoma 1996;23:221-226.
2. Nademanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS, O'Donnell M, Smith EP, Stepan DE, Molina A, et al: The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995;86:1228-1234.
3. Davison GM, Novitzky N, Kline A, Thomas V, Abrahams L, Hale G, Waldmann H: Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000;69:1341-1347.
4. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, et al: T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-2130.
5. Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, Appelbaum FR, Clift R, Fefer A, Witherspoon RP, et al: Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985;66:664-672.
6. Enright H, Davies SM, Defor T, Shu X, Weisdorf D, Miller W, Ramsay NK, Arthur D, Verfaillie C, Miller J, Kersey J, Mcglave P: Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective. Blood 1996;88:714-720.
7. Gale RP, Horowitz MM: Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1990;6(suppl 1):94-97.
8. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
9. Huber BE, Austin EA, Richards CA, Davis ST, Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994;91:8302.
10. Wei MX, Tamiya T, Chase M, et al: Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994;5:969.
11. Knox RJ, Friedlos F, Boland MP: The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev 1993;12:195-212.
12. Thomis DC, Marktel S, Bonini C, et al: A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001;97:1249-1257.
13. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: Hsv-tk gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-1724.
14. Tiberghien P: Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation. J Intern Med 2001;249:369-377.
15. Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E, Certoux JM, Robinet E, Saas P, Petracca B, Juttner C, Reynolds CW, Longo DL, Herve P, Cahn JY: Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001;97:63-72.
16. Tiberghien P, Cahn JY, Brion A, Deconinck E, Racadot E, Herve P, Milpied N, Lioure B, Gluckman E, Bordigoni P, Jacob W, Chiang YW, Marcus S, Reynolds C, Longo D: Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation - A phase I-II study. Hum Gene Ther 1997;8:615-624.
17. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-4242.
18. Orchard PJ, Blazar BR, Burger SR, Levine B, Basso L, Nelson DMK, Gordon K, McIvor RS, Wagner JW, Miller JS: Clinical scale selection of anti-CD3/CD28 activated T cells following transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Hum Gene Ther 2002;13:979-988.
19. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-223.
20. Mavilio F, Ferrari G, Rossini S, Nobili N, Bonini C, Casorati G, Traversari C, Bordignon C: Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994;83:1988-1997.
21. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA: HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990;9:1551-1560.
22. Anderson PM, Bach FH, Ochoa AC: Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma. Cancer Immunol Immunother 1988;27:82-88.
23. Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH: Lymphokine- activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: Identification and isolation of effector subsets. Cancer Res 1989;49:963-968.
24. Levine BL, Ueda Y, Craighead N, Huang ML, June CH: CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol 1995;7:891-904.
25. Levine BL, Mosca JD, Riley JL, Carroll RG, Vahey MT, Jagodzinski LL, Wagner KF, Mayers DL, Burke DS, Weislow OS, ST, L.D., June, CH: Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996;272:1939-1943.
26. Levine BL, Cotte J, Small CC, Carroll RG, Riley JL, Bernstein WB, Van Epps DE, Hardwick RA, June CH: Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998;7:437-448.
27. Garlie NK, Lefever AV, Siebenlist RE, Levine BL, June CH, Lum LG: T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother 1999;22:336-345.
28. Shibuya TY, Wei WZ, Zormeier M, Ensley J, Sakr W, Mathog RH, Meleca RJ, Yoo GH, June CH, Levine BL, Lum LG: Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2000;126:473-479.
29. Wolf H, Muller Y, Salmen S, Wilmanns W, Jung G: Induction of anergy in resting human T lymphocytes by immobilized anti- CD3 antibodies. Eur J Immunol 1994;24:1410-1417.
30. Noel PJ, Boise LH, Green JM, Thompson CB: CD28 costimulation prevents cell death during primary T cell activation. J Immunol 1996;157:636-642.
31. Radvanyi LG, SHI Y, Vaziri H, Sharma A, Dhala R, Mills GB, Miller RG: CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 1996;156:1788-1798.
32. Muller Y, Wolf H, Wierenga E, Jung G: Induction of abortive and productive proliferation in resting human T lymphocytes via CD3 and CD28. Immunology 1999;97:280-286.
33. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
34. Jaffee EM, Dranoff G, Cohen LK, Hauda KM, Clift S, Marshall FF, Mulligan RC, Pardoll DM: High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993;53:2221-2226.
35. Gallardo HF, Tan C, Sadelain M: The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther 1997;4:1115-1119.
36. Zitvogel L, Tahara H, Cai Q, Storkus WJ, Muller G, Wolf SF, Gately M, Robbins PD, Lotze MT: Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther 1994;5:1493-1506.
37. Bahnson AB, Dunigan JT, Baysal BE, Mohney T, Atchison RW, Nimgaonkar MT, Ball ED, Barranger JA: Centrifugal enhancement of retroviral mediated gene transfer. J Virol Methods 1995;54:131-143.